Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats

Journal of Cardiovascular Pharmacology
K SakaiM Tanikawa

Abstract

We examined a relation between cyclic guanosine monophosphate (cGMP) production in thoracic aorta, as an indicator probably reflecting the vascular response, and the vascular as well as plasma levels of nicorandil administered orally to rats. Nicorandil (3 mg/kg) given orally was rapidly absorbed, reaching the maximal plasma (approximately 2,600 ng/ml) and vascular concentrations (approximately 176 ng/g) at 15 min after the dosing and thereafter decreased rapidly. Even 2 h after the dosing, the level of the vascular cGMP formation in vivo remained significantly higher (approximately 1,000 fmol/mg increase from the control level) in the nicorandil-treated group, compared with the vehicle-treated one, and was enough to develop pronounced muscle relaxation in in vitro aortic preparations. However, it seems that the vascular cGMP increase in vivo was not always correlated to the plasma concentration of nicorandil, because the plasma concentration (approximately 750 ng/ml corresponding to 3.5 microM) at 2 h after the dosing, caused only relatively low cGMP production (300-400 fmol/mg increase from the control level), when tested in in vitro aortic preparations. Our study may indicate, therefore, that the vascular cGMP elevation in v...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·W R KukovetzG Pöch
Jan 1, 1992·Journal of Cardiovascular Pharmacology·A Frydman
May 1, 1990·Journal of Cardiovascular Pharmacology·K J MorrisonP M Vanhoutte
Aug 1, 1990·Cardiovascular Drugs and Therapy·M Kinoshita, K Sakai
Mar 1, 1990·The American Journal of Physiology·T M LincolnA E Taylor
Jan 1, 1988·Life Sciences·D J Lefer, A M Lefer
Jun 20, 1989·The American Journal of Cardiology·N Taira
Jun 20, 1989·The American Journal of Cardiology·K Sakai
Jan 1, 1985·Annual Review of Pharmacology and Toxicology·L J Ignarro, P J Kadowitz
Nov 1, 1988·European Journal of Pharmacology·H KarakiK Murakami
Mar 26, 1997·European Journal of Pharmacology·T KawadaS Imai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.